Digging Deeper Into This Heart Failure Drug's Miss Motley Fool Before the market opened last Tuesday, Cytokinetics (NASDAQ: CYTK ) and Amgen (NASDAQ: AMGN ) scrambled to spin the results of their Phase 2 ATOMIC-AHF trial for heart failure drug omecamtiv mecarbil. The results were presented for the first time at ... |
